ArticleCureus2025
Amyloid Positron Emission Tomography Imaging at the Onset of Amyloid-Related Abnormalities With Edema in an Alzheimer's Disease Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Donanemab-associated clinical improvement in Alzheimer's disease presenting predominantly with neuropsychiatric symptoms: A case report.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid-related imaging abnormalities with edema (ARIA-E) are known adverse events of anti-amyloid monoclonal antibody therapy for Alzheimer's disease (AD), but to our knowledge, amyloid positron emission tomography (PET) captured exactly at the moment of ARIA-E onset has not previously been reported. We report an 85-year-old woman with AD who received anti-amyloid antibody therapy for approximately one year. As part of routine post-treatment evaluation, a second amyloid PET scan obtained 16 days after her final infusion unexpectedly revealed asymptomatic ARIA-E when followed immediately by magnetic resonance imaging (MRI). Compared with the baseline, the follow-up PET showed a marked overall reduction in cortical amyloid burden, including near-complete loss of tracer uptake in the region corresponding to ARIA-E, while the adjacent white matter exhibited reduced, non-specific uptake likely related to edema. This unique, same-day PET-MRI pairing at the moment of ARIA-E detection highlights dynamic regional changes in amyloid signal during treatment and emphasizes the value of continued neuroimaging surveillance even in asymptomatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.